Abstract 928P
Background
The prediction of early response in locally advanced nasopharyngeal carcinoma (LA-NPC) after concurrent chemoradiotherapy (CCRT) is indeed important for determining the need for timely consolidation therapy. Radiomics has helped medical imaging expand from diagnostic to a personalized clinical decision aid, while most traditional radiomics primarily focus on mono-sequence. Recently, multi-MR sequences model has shown better outcomes in the management of many cancers. However, the validation of a radiomic analysis of multi-MR sequences based on machine learning for this purpose is currently lacking for patients with LA-NPC after CCRT.
Methods
This study comprised 104 patients with LA-NPC, of which 70% were allocated for training and the remaining 30% were used for internal validation. We extracted radiomics features corresponding to each mono-sequences (T1, T1C, T2, DWI, and ADC), and then applied LASSO for feature selection and constructed the risk model using machine learning algorithms including SVM, Random Forest, ExtraTrees, XGBoost and LightGBM. Performance comparisons were made between mono-sequences and then feature fusion was performed to construct a multi-MR sequences model. Clinical features were numerically mapped and analyzed using machine learning algorithms similar to those in the Radiomics Model. Finally, we created a combined model that integrated the radiomics and clinical models to enhance clinical relevance, whose diagnostic effectiveness was evaluated using receiver operator characteristic (ROC) curves in the test cohort.
Results
In the training cohort, while the Clinic model achieved an Area Under the Curve (AUC) of 0.892 and the Fusion model reached 0.972, the Combined model excelled with an AUC of 0.990. Similarly, in the test cohort, the Combined model outperformed both the Clinic (AUC: 0.852) and Fusion models (AUC: 0.886), achieving an AUC of 0.900.
Conclusions
As a result, a combined model, which merges clinical and multi-MR sequences radiomics model, showed good performance for predicting early response of LA-NPC after CCRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Province Entrepreneurship and Innovation Doctoral Talent Program and Jiangsu Province People's Hospital Clinical Capability Enhancement Project.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1046P - Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapy
Presenter: Yi Hu
Session: Poster session 03
Resources:
Abstract
1047P - Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis
Presenter: Michel Obeid
Session: Poster session 03
1048P - Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 03
1049P - Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective study
Presenter: Mariam Shalaby
Session: Poster session 03
1050P - Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAE
Presenter: Sarah Roffeis
Session: Poster session 03
1051P - Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitors
Presenter: Antoine Italiano
Session: Poster session 03
Resources:
Abstract
1052P - Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signatures
Presenter: Elisabetta Nale
Session: Poster session 03
1053P - The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Presenter: Abdulrahman Alghabban
Session: Poster session 03
1054P - CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment
Presenter: Mariano Provencio Pulla
Session: Poster session 03
1055P - Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancers
Presenter: Annarita Avanzo
Session: Poster session 03